BINGO! Article from January 13, 2017.

In loking at your first post here, I get where you are coming from, those bastards should all be in jail.

Nice chatting!


CHEVYGUY Sunday, 06/01/08 05:09:05 PM
Re: pphmlover post# 23918 0
Post # of 328882
OK I HAVE BEEN WATCHING FOR SOME TIME AND WOULD LIKE SOME ANSWERS

1 WHY IS THERE NO INSIDER BUYING IF THEY KNOW BAVI IS GOOD?

2 IF THE DUKE PAPERS ARE SO GREAT WHY IS THE VOLUME NOT MOVING? DUKE IS A BIG MONEY PLACE AND IF SOMEONE KNEW ANYTHING IT WOULD SPREAD LIKE WILDFIRE AND VOLUME WOULD BE UP.

3 WHY WOULD TK TAKE A P1 DRUG WHEN THERE ARE MANY MORE IN P3?

4 WHAT HAPPENED BIG ON TARVY TO THE BOD SAYING THIS STOCK WAS WORTH 11 BUCKS AND NOW ITS SITTING AT 40 SOME CENTS?

5 WHERE WILL PPHM GET MONEY?

6 WHY DOES JAZZ KEEP POSTING STUFF THAT PEOPLE THINK PPHM HAS ANYTHING TO DO WITH?

7 WHY DOES ANYONE THINK BAVI WILL COME TO MARKET BEFORE 3-5 YEARS? AVERAGE TRIAL TIME IS 7-9 YEARS

MY OBSERVATION IS THAT THEY HAVE NOTHING AND THATS WHY THEY CANT GIVE ANY INFO BECAUSE THERE IS NONE.

I AM SURE EVERYONE THINKS I AM BASHING BUT THERE ARE NO REAL REASONS THIS STOCK WILL MOVE.

"Rome wasnt built over night."

I thought it was a "day"!

Just so we are clear on how long to expect to wait.

"Rome ne s'est pas faite en un jour"

"The negotiators say they have until December, when the current Congress is expected to adjourn, to finalize a new bill. The House is expected to adjourn this week until after the Nov. 6 elections."

"We’re continuing on, committed to working through October and committed to getting this done before the end of the year,” said Sen. Debbie Stabenow, the ranking Democrat on the Senate Agriculture Committee.

BINGO! Your article is from Aug. 17, 2016.

When does Mr. Sid arrive to take this to the next level?

This sub a $1, I mean sub $7 level is getting old.

From another article.........

http://www.nutritionaloutlook.com/trends-business/cv-sciences-launches-cbd-gummy-marketed-functional-food


Correction made 9/19/18 at 9:00 AM EST: A previous version of this article stated that all PlusCBD Oil products had GRAS self affirmation. This has been revised to say only the Gold Formula is self-affirmed GRAS.

CV Sciences, Inc. Announces a New Category of Its Industry-Leading PlusCBD Oil™ Products, Hemp Extract Gummies

GlobeNewswire•September 25, 2018

LAS VEGAS, Sept. 25, 2018 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”) preeminent supplier and manufacturer of hemp-derived phytocannabinoids including industry leading brand, PlusCBD Oil™ , announced today that it has introduced PlusCBD Oil™ Gummies at the Natural Product Expo East 2018.

A new category of PlusCBD Oil™ products, PlusCBD Oil™ Gummies are offered in two tasty flavors, Cherry Mango and Citrus Punch. A line extension of our Gold Formula line with no artificial ingredients, each gummy contains 5 mg of CBD and a mere 1.5 g of sugar. Gluten free, vegan friendly, and non-GMO, these new products support healthy balance of the body and mind.

“We are pleased to introduce PlusCBD Oil™ Gummies to our existing line of industry leading hemp extract products that include balms, sprays, drops, capsules, and softgels,” stated Joseph Dowling, Chief Executive Officer of CV Sciences. “We are committed to innovation of our PlusCBD Oil™ products, and as the demand for CBD infused products continues to grow, it is important to expand our wide variety of products to suit all customer preferences. We foresee PlusCBD Oil™ Gummies being a solid revenue driving category for our Company.”

About CV Sciences, Inc.
CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784

"Did he get the shares for 2.25 is there a deal he can move into that is super attractive."

That pretty much sums up CDMO, not super attractive.

As a Ronin BOD select, as long as he's not buying back at $5 in a month or two then it's no big deal IMO.

Maybe he just wants to buy a new car.

"....here comes the bounce back!!!"

Not to bad! You are only down .13 cents on your buy from this morning.

Monday should be better.

Have a great weekend!

My question was why did you buy at $5.22 when the price is $4.87???

DUH! LMAO

I would agree. The news is actually positive for CVSI, unfortunately we are trending with the group.

Good opportunity to buy more lower.

Reading the news helps better explain CVSI's drop.

UPDATE: GOP congressman questions Tilray medical-cannabis imports to U.S.

7:24 am ET September 21, 2018 (MarketWatch)
Share
Print
By Max A. Cherney

Florida Republican Matt Gaetz wants U.S. firms to supply clinical trial

U.S. Rep. Matt Gaetz, a Florida Republican who is spearheading a medical cannabis reform law, has questioned this week's decision to allow Canada-based Tilray Inc. to import the drug for use in a clinical trial.

Tilray announced early Tuesday that the U.S. Drug Enforcement Administration signed off on the company's plan (http://www.marketwatch.com/story/tilray-to-import-cannabis-to-us-for-clinical-trial-2018-09-18) to import a marijuana product from Canada in order to test its effectiveness in treating essential tremor. In an interview with MarketWatch on Thursday, Gaetz said the U.S. has the opportunity to build its own cannabis industry and he sees little reason to divert potential wealth to Canada.

"We just have to be not so stupid as to impair our own progress," Gaetz said in a phone interview. "There is no reason for us to be creating wealth in Canada for cannabis companies by importing Canadian weed."

(

Unbelievable...#DEA gives approval to import #cannabis compounds from Canada, while AG Sessions is sitting on 2 dozen+ applications from domestic manufacturers. What happened to “buy American, hire American”?https://t.co/SAiftyoN32

— Rep. Matt Gaetz (@RepMattGaetz) September 19, 2018

)

Gaetz has been outspoken about the importance of medical research into cannabis for some time. Currently in the U.S., only the University of Mississippi is licensed to grow and harvest research-grade marijuana plants. More than 25 U.S.-based manufacturers have reportedly applied to the DEA (https://thehill.com/policy/healthcare/public-global-health/382858-hatch-harris-call-for-doj-to-stop-blocking-medical) to produce cannabis, but no action has been taken on those applications while Tilray was granted approval.

The lack of action is squarely the DEA's fault, Gaetz said, pointing a finger at former acting head Robert Patterson and calling his lack of knowledge about the industry "embarrassing." Following Patterson's testimony earlier this year (), Gaetz said it was "easy" to see why the DEA hadn't approved more American companies for medical cannabis production.

For Tilray's part, spokesman Zack Hutson said Thursday that the company is American and would be "delighted" to produce cannabis in the U.S. But, he said that it's currently not feasible to do so under U.S. federal law, and thus the next best option is to import cannabis from its facilities in Canada.

"If Congress changes the law to allow for commercially feasible production of pharmaceutical-grade medical cannabis, we'd be thrilled to create jobs and invest in the U.S. just like we have in Canada," Hutson said in an email to MarketWatch. "We agree with Representative Gaetz that the U.S. federal government should enable instead of impede this rapidly growing, global and innovative industry. In the meantime patients and researchers in need shouldn't have to wait on quality products to conduct critical scientific and medical research."

"Back in today at $5.22, $CVSI"

WHY?

Unfortunately a big RED candle.

""We don't have a choice on that,” she said. “It absolutely has to become Schedule 2 or 3."

Which means MEDICAL GRADE CBD, in this case Epidiolex, will be legal but still be classified as a "prescription drug" just not in the same class as say heroin which is Schedule 1.


FROM FORBES

Is DEA Being Forced To Reschedule The CBD Compound?

Mike Adams

It has been said that 2018 will go down in history as one of the biggest years in the grand scheme of cannabis reform. Not only did Canada legalize the leaf nationwide for recreational use, but also the U.S. Food and Drug Administration (FDA), one of the gatekeepers to “safe and effective” medicine in the United States, admitted that parts of the cannabis plant, something that the U.S. government has considered a gateway to addiction and social downtrodden for the past several decades, has a place in the treatment of patients suffering from severe forms of epilepsy.

The federal agency recently gave Britain’s GW Pharmaceuticals' cannabis-based drug Epidiolex, which is comprised of pure cannabidiol (CBD), the green light for distribution in pharmacies all across the nation. This is the first time ever that anything derived from the cannabis plant has been considered fit to mingle with the likes of the American healthcare industry. This, of course, is big. But there is one unsung detail that even is bigger. It seems that tucked inside this major development is a minute reform that no one seems to be talking about – the fact that CBD must now be rescheduled by the U.S. Drug Enforcement Administration (DEA).

It was just a few weeks ago that the FDA gave GW Pharmaceuticals permission to start slinging Epidiolex to epilepsy patients here in the states. The solution, which has been shown effective in reducing seizures in children with Lennox-Gastaut syndrome and Dravet syndrome, will soon be available with a prescription through all major pharmacy chains from Walgreens to CVS. This is significant considering that the federal government still considers any derivative of the cannabis plant a Schedule I dangerous drug – a substance that resides in the same dark closet with heroin. This despite the fact that cannabidiol (CBD) is a non-intoxicating part of marijuana. Even when consumed in large doses, it is impossible to get high from it.

But now that the FDA considers Epidiolex a “safe and effective” treatment option for certain forms of epilepsy, CBD must be downgraded to a Schedule II or III on the DEA’s Controlled Substances Act.

Barbara Carreno, a public affairs representative for the DEA, recently told Business Insider that the agency has 90 days to put CBD into a lower classification. The change is already in progress. Unlike with past petitions aimed at getting cannabis downgraded to a less restrictive classification, the DEA’s pending action with respect to the CBD deal is a prerequisite to the launch of Epidiolex.

MORE FROM FORBES
"We don't have a choice on that,” she said. “It absolutely has to become Schedule 2 or 3."

A reschedule of the CBD compound is necessary to uphold the Controlled Substance Act. Because CBD’s current listing as a Schedule I drug suggests that it has “no known medicinal value,” the FDA cannot allow Epidiolex to go to market without making a change. It is the same reason that opioid medications, like OxyContin and Percocet, are listed as Schedule II even though these narcotics are essentially the same drug as heroin – listed Schedule I. It’s Uncle Sam’s sneaky way of skirting its own rules in the interest of profits. Just ask Hustler magazine publisher and cannabis investor Larry Flynt.

Sadly, not much is expected to change from a CBD reschedule. In reality, the cannabis scene probably will not experience any difference at all. At best, the DEA tossing CBD into a Schedule II or III classification will open up some additional research opportunities that have been sandbagged under Schedule I. That’s about the extent of it. But this doesn’t mean it will be easier for the scientific community to explore the medicinal benefits of whole plant marijuana. The FDA recently rejected a petition to include Tetrahydrocannabinol (THC) and other cannabis derivatives on its list of over-the-counter medications that are considered safe and effective. The agency basically said that while no additional federal restrictions would be imposed on the herb, it was not being let out of its cage.

Furthermore, FDA Commissioner Scott Gottlieb is not keen on certain kinds of medical marijuana. He said recently that the agency would likely never hand down approval for a cannabis product as long as it was presented in smokeable form. Not impossible -- just not probable.

“Using a lung as a drug delivery vehicle isn’t optimal,” he said. “That’s not to say that we wouldn’t evaluate it if it came in; it just wouldn’t be an optimal way to deliver an active ingredient.”

If marijuana ever finds its way to nationwide legalization in the U.S. in a manner similar to beer, a modified version of the Alcohol and Tobacco Tax and Trade Bureau (TTB), not the FDA, would be responsible for regulating most cannabis products.

But as long as marijuana is considered a Schedule I dangerous drug, any research geared toward the discovery of therapeutic properties will remain almost non-existent. What’s more is a CBD reschedule will do nothing to alleviate the conflict between state and federal law. Sure, it will be easier for doctors nationwide to prescribe medical grade CBD to some of their patients. But since Epidiolex is the only FDA-approved medication of its kind -- and it is exclusively for children with epilepsy -- patients with conditions ranging from chronic pain to cancer will not be prescribed the drug as an alternative to traditional medications.

In order for a situation like that to open up, members of the cannabis industry would have to pull together some mega-bucks to seek FDA-approval for their respective products. It is a process that costs billions of dollars to bring to fruition. It is unlikely, at this juncture, that even the most successful cannabis company has the resources to take such an ambitious plunge into the American drug game.

But the FDA says it is open to it if they want to give it a try.

“We support sound, scientifically-based research using components derived from marijuana, and we’ll continue to work with product developers who are interested in bringing safe, effective, and quality products to market,” Gottlieb said last year in a statement.

Once CBD is rescheduled, cannabis companies will still not have the freedom to make unsubstantiated claims about their cannabis products. Any business telling customers that their CBD oil shrinks tumors or cures cancer is likely to catch some heat. As far as the FDA is concerned, the only benefit CBD provides is making life more palatable to some patients with severe seizure disorders. Nothing more.

Cannabidiol (CBD) Infused Personal Care Products Industry Becoming More Mainstream With More Consumers

8:55 am ET September 20, 2018 (PR Newswire) Print
MarketNewsUpdates.com News Commentary

Personal Care and Healthcare products infused with cannabidiol (CBD) are rapidly becoming the product du jour. Derived from the hemp plant, a cousin to marijuana, CBD boasts a number of health and skin benefits because of its rich in fatty acids and natural emollients. When applied topically, it can even help reduce oil production and therefore has been shown to have some anti-acne and anti-inflammatory characteristics. Explosive growth in the hemp-derived CBD category that has grown from a market category that did not exist five years ago to $190 Million in sales in 2017 is poised to reach a $1.0 Billion market in 2018 led by hemp-derived CBD, food, personal care and industrial products. Hemp Business Journal estimates the U.S. hemp industry will grow to a $1.9B market by 2022 giving reason more and more are jumping into this lucrative market. Active companies in the Cannabis markets this week include Cannabis Strategic Ventures, Inc. (OTC:NUGS), Tilray Inc. (NASDAQ:TLRY), MARIJUANA COMPANY OF AMERICA INC. (OTC:MCOA), Medical Marijuana, Inc. (OTC:MJNA), CV Sciences, Inc. (OTC:CVSI).

Cannabis Strategic Ventures, Inc. (OTCPK:NUGS) BREAKING NEWS: Cannabis Strategic Ventures and True Promise Beauty announce the development of LYXR, a new line of cannabidiol (CBD)-based luxury skin, hair and body products. LYXR products are developed from a line of hemp-derived phytocannabinoids, and other natural ingredients that provide high-performing skin, hair and body topical solutions.

For LYXR's inaugural product, Cannabis Strategic Ventures and True Promise Beauty have developed a facemask, which is made from a CBD isolate. CBD isolate is believed to have anti-inflammatory, analgesic, anti-oxidant properties that helps to regenerate cells, as well as, prevent the formation of bad cells (anti-cell proliferation). Additional mask proprietary ingredients will provide hydrating and anti-aging/age prevention benefits. The LYXR product line will eventually include skin, hair and body products.

"For Cannabis Strategic Ventures, LYXR represents a tremendous opportunity to marry cannabis science with an increasing global demand for luxury personal care products," said Simon Yu, CEO, Cannabis Strategic Ventures. "More relaxed cannabis laws and an increased support for cannabis research are further legitimizing the claims surrounding CBD's healing abilities."

True Promise Beauty was developed by Emmy Award-Nominated Hollywood Make-Up Artist, Gail Johnson. The inspiration for True Promise Beauty was to help address the real concerns of actors and actresses working in High-Definition, where even tiny lines and wrinkles can no longer be hidden by conventional makeup and lighting techniques. True Promise Beauty products were designed to instantly smooth out fine surface lines and give a matte finish upon application leaving the user with a smoother canvas for makeup application. Through True Promise Beauty, Johnson established distribution channels with L'Oreal, Salon Centric and Beauty Systems Group. True Promise Beauty and Cannabis Strategic recently announced a joint venture agreement to develop proprietary CBD skincare line as part of Cannabis Strategic's family of brands.

"True Promise Beauty and Cannabis Strategic Ventures will create a unique product grouping that has not previously been seen in the marketplace," said Gail Johnson, President, True Promise Beauty, Inc. "CBD coupled with our chemists' viable formulas will literally revolutionize the topical approach to skincare, haircare and bodycare industries. With LYXR, we are now entering a new era where we will offer products that not only provide age reversing/age preventative properties, but the scientifically proven data that CBD is at once anti-inflammatory, analgesic, anti-oxidant, cell regenerative and anti-cell proliferative." Read this and more news for Cannabis Strategic Ventures at: http://www.marketnewsupdates.com/news/nugs.html

Other recent developments and major influences in the cannabis industry include:

MARIJUANA COMPANY OF AMERICA INC. (OTCPK:MCOA), an innovative hemp and cannabis corporation, and its joint venture partner Global Hemp Group Inc. (GHG.F) (GBHPF) recently provided an update on their CBD hemp farming joint venture in New Brunswick, Canada. Highlights include: Dryer Installation - Drying of the biomass is an important first step in the extraction of the cannabinoids from the hemp plant. The partners are pleased to announce that the Project's industrial scale dryer from Cann Systems was delivered last week and has now been installed. >> Innovation in the Hemp Industry - It is now nearing harvest time at the New Brunswick Hemp Project. To maximize profit, it is important to harvest as much of the higher CBD content flowers and leaves as possible, without undue amounts of the low to no CBD straw (the stalk). This year's drought has complicated matters as the hemp plants have tended to be shorter than usual, and the weeds are taller as they were able to get a head start before the hemp began growing, although the hemp is still displaying very healthy and weighty inflorescence. >> New Research Collaboration - The drought in northeast New Brunswick has not affected all fields uniformly. One of our fields is reported by DAAF field agrologists as "one of the finest of the province". Aside from the obvious economic benefit in terms of increased yields, this field offers the opportunity to contrast high and low performing plants of a given variety in the same location, shedding some light on the role of plant nutrition in explaining the performance of hemp plants. Dr. Ron Smith from University of New Brunswick will spearhead a research project focused on the issue.

Tilray Inc. (NASDAQ:TLRY) the week announced that the U.S. Drug Enforcement Administration (DEA) has granted approval to import a cannabinoid study drug into the United States from Canada for a clinical trial at the University of California San Diego (UC San Diego) Center for Medicinal Cannabis Research (CMCR) examining its safety, tolerability and efficacy for Essential Tremor (ET). Tilray is providing a cannabinoid formulation for the trial in capsule form, which will allow researchers to test an investigational drug product containing two active ingredients extracted from the cannabis plant, cannabidiol (CBD) and tetrahydrocannabinol (THC). Dr. Fatta Nahab, a board-certified neurologist and director of the Functional Imaging of Neurodegenerative Disorders Lab at the UC San Diego Health's Movement Disorder Center, will serve as the principal investigator for the study. It is expected to begin in early 2019 with financial support from Tilray and the International Essential Tremor Foundation.

Medical Marijuana, Inc. (OTCPK:MJNA) recently announced today that its subsidiary Kannaway(R) has garnered international news coverage in leading daily news publication, The Wall Street Journal. A September 12, 2018 article in The Wall Street Journal website titled "Cannabis Comes to Your Coffee and Candy-But Is It Legal?" discusses the recent popularity of cannabidiol (CBD) products around the world, highlighting the inclusion of CBD in many new food and beverage products and the complex legality of CBD in the United States. The article features commentary and cited quotes from a Kannaway(R) executive explaining that everyday consumers, including moms, are catching on to the popularity of CBD; and how bars and restaurants are also using CBD to enhance their menu offerings and attract more customers. "Kannaway is honored to be included of this article and the ongoing conversation surrounding CBD and its health and therapeutic benefits," said Kannaway(R) CEO Blake Schroeder. "We want to continue spreading awareness of the many benefits of CBD and that people of many backgrounds can incorporate it into their everyday lives."

CV Sciences, Inc. (OTCQB:CVSI) recently stated that the Company would like to assure our shareholders that we are keenly aware of recent market activity and certain disinformation disseminated by persons holding short positions in our stock. "As many of our shareholders are aware, our Company has been victimized by campaigns run by short sellers in order to depress our stock price, so they could make financial windfalls," stated Joseph Dowling, Chief Executive Officer of CV Sciences. "We are also aware that at least one such group has boasted on social media platforms about its financial returns since their release of misleading information regarding the Company's patent prosecution and drug development efforts." Mr. Dowling continued, "While we don't normally comment on our stock price or performance, it is important to stress that nothing has fundamentally changed in our business. We continue to deliver solid financial results, and we remain very confident in our prospects.".

DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated twenty five hundred dollars for news coverage of the current press releases issued by Cannabis Strategic Ventures, Inc by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Media Contact: info@marketnewsupdates.com +1(561)325-8757

SOURCE MarketNewsUpdates.com

"Better hurry and buy at opening."

With "Video Chart" guy here you might want to wait as the shorts will probably be all over this today.

Should read PPHM. Don't go to jail, don't admit guilt, just pay fine and move on to next scam!


Biopharmaceutical company fined for misleading investors

From Associated Press
September 19, 2018 11:36 AM EST

BOULDER, Colo. (AP) — A Colorado-based biopharmaceutical company has been penalized more than $20 million for misleading investors about the efficacy of a lung cancer drug under development before raising $300 million in a public stock offering.

The U.S. Securities and Exchange Commission brought the complaint against Clovis Oncology Inc., of Boulder, and two company executives — CEO Patrick Mahaffy and former chief financial officer Erle Mast, the Daily Camera newspaper reports .

In a complaint filed in U.S. District Court in Denver, federal regulators said Clovis Oncology reported in May 2015 that its lung cancer drug was effective in reducing the size of tumors 60 percent of the time. They did not disclose updated data that showed the efficacy was actually 42 percent before its July 2015 stock offering that raised $300 million, the SEC alleged.

Clovis Oncology stock traded as high as $116 in mid-September 2015 and collapsed to $26 a share in mid-November 2015 after Clovis disclosed the drug's actual efficacy rate was 28 percent. The company stopped developing the drug in May 2016, with the stock trading in the $12 range.

Clovis shares were trading at $32.50 on Wednesday.

The company is required to pay a $20 million penalty, Mahaffy must pay $250,000 and Mast must pay $100,000 under an agreement that settled the complaint that alleged violations of federal securities law.

The SEC also alleged Mast sold company stock at artificially inflated prices and required him to repay the proceeds, plus interest, for an additional $454,000 penalty.

A Clovis Oncology spokeswoman declined to comment. The company and its executives did not admit or deny the allegations in the settlement, the SEC said.

Previous bump up $4.50 to $6.50 then back to $5.30.....$5.75 range lasted for a month. Here we are again, $5.50 up to $7.50 and back to $6.40. Will we stay here for another month taking us to the ASM?

I thought Ronin had to report sometime in September. Would love to know what they are up to other then manipulating the stock.

"Buy some trading stocks now and in a couple of days it will be 7 again."

Absolutely and depending on who owns all those $7.50 September calls we might just see $7.50 before the month's over.

Coca-Cannabis? Coke analyzing cannabis in wellness drinks

https://www.usnews.com/news/business/articles/2018-09-17/coca-cola-closely-watching-cannabis-in-wellness-drinks

Coca-Cola adds ... cannabis? Company says it's "closely watching" the growth of non-psychoactive element of cannabis in wellness drinks.

BY GILLIAN FLACCUS, Associated Press

The Coca-Cola Company said Monday it is "closely watching" the expanding use of a cannabis element in drinks, another sign cannabis and cannabis-infused products are getting more acceptance in mainstream culture and a harder look from long-established pillars of American business.

The statement came after reports the beverage giant was in talks with a Canadian cannabis company to create a health drink infused with cannabidiol, a naturally occurring non-psychoactive compound derived from the cannabis plant. Shares of the company, Aurora Cannabis Inc., closed up nearly 17 percent on the Toronto Stock Exchange after the report.

Spokespeople for the companies declined to comment on the report but acknowledged their interest in that segment of the cannabis market.

Cannabidiol, or CBD, does not produce the high commonly associated with marijuana. It is believed by many to have anti-inflammation and pain-relieving properties, and numerous CBD-infused products have emerged recently.

Aurora spokeswoman Heather MacGregor said her company "has expressed specific interest in the infused-beverage space and we intend to enter that market."

A Coke spokesman said the beverage giant has made no such decision.

"Along with many others in the beverage industry, we are closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world. The space is evolving quickly," Coke spokesman Kent Landers said.

Coke's interest is another indication of the growing acceptance of cannabis by established companies and of the importance of Canada to the development of those businesses. Marijuana becomes legal across Canada on Oct. 17. Cannabis companies from the U.S. — where marijuana remains illegal at the federal level — have flocked to Canada to raise funds and establish businesses there.

American companies interested in making a play in the cannabis space can try things out in Canada without risking doing something illegal at home.

Constellation Brands, a giant spirits company that counts Corona beer among its labels, bought a multibillion-dollar minority stake in Canopy Growth, a Canadian medical marijuana producer.

Coca Cola's statement shows the company has learned from its past missteps picking up on new drink trends, said Ali Dibadj, a senior analyst at AllianceBernstein with an expertise in U.S. beverage and snack food companies.

"The company has been caught flat-footed in the past in not keeping up with trends in beverages. They missed the energy drink phenomenon, they missed — and then had to buy into — the functional waters like Vitamin Water and coffee," Dibadj said. "I think what they're saying is what they should be saying on this very new and emerging beverage."

But testing the waters of cannabis-themed drinks could backfire, he said. Many Americans aren't intimately familiar with the cannabis plant and might not understand that CBD has no psychoactive properties.

Hemp and marijuana are both cannabis plants, and both contain CBD, which can be extracted as an oil that can be added to everything from dog food to hand lotion to drinks.

"I think you have to be very, very careful with this as a large brand. There are different viewpoints on a product category, and you don't want to offend too much," Dibadj said. "You don't want to be too far ahead on any curve."

____

Flaccus is a member of AP's marijuana beat team. Follow her on Twitter at https://twitter.com/gflaccus. Follow complete AP marijuana coverage: https://apnews.com/tag/LegalMarijuana

"Did a search on the NASDAQ site"

"but shouldn't it have NOT come up if not listed??"

I guess this shouldn't have come up either.........

https://www.nasdaq.com/symbol/potn

You posted it like FAKE news.

A bit of a reach, where do they mention CDMO?


Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada


Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Intraday Stock Chart
Today : Monday 17 September 2018


SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Roche has received approval from Health Canada for a subcutaneous (SC) formulation of trastuzumab (Herceptin SC) for the treatment of patients with HER2-positive breast cancer. This is a co-formulation with Halozyme's proprietary recombinant human hyaluronidase enzyme (ENHANZE® technology).

"We are pleased that the subcutaneous formulation of trastuzumab (Herceptin SC) has been approved in Canada," said Dr. Helen Torley, president and chief executive officer. "Patients and health care providers will now have another treatment option with the potential for a reduced administration time."

The U.S. Food and Drug Administration accepted a Biologics License Application from Genentech for a subcutaneous (SC) formulation of trastuzumab (Herceptin SC) in July 2018.

About ENHANZE® Technology
Halozyme's proprietary ENHANZE® drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20). rHuPH20 has been shown to remove traditional limitations on the volume of biologics that can be delivered subcutaneously (just under the skin). By using rHuPH20, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously. ENHANZE may also benefit subcutaneous biologics by reducing the need for multiple injections. This delivery has been shown in studies to reduce health care practitioner time required for administration and shorten time for drug administration.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the potential to be used in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb and Alexion for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Halozyme Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the Company's future expectations and plans for growth in 2018, entering into new collaboration agreements, the development and commercialization of product candidates, including timing of clinical trial results announcements and future development and commercial activities of our collaboration partners, the potential benefits and attributes of such product candidates and expected financial outlook for 2018) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected fluctuations or changes in revenues, including revenues from collaborators, unexpected delays in entering into new collaboration agreements, unexpected results or delays in development of product candidates, including delays in clinical trial patient enrollment and development activities of our collaboration partners, and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2018.

Contacts:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
858-356-5932
robert.uhl@westwicke.com

Laurie Stelzer
858-704-8222
ir@halozyme.com

FROM THE FORM...you left out one part.

"commencing on August 4, 2018."

Stock Option (RIGHT TO BUY)
(1)
Expiration Date 08/03/2028

Amount or Number of Shares Common Stock

250,000 @ $2.95

He's exercising his OPTION right to buy.

https://s3.amazonaws.com/content.stockpr.com/sec/0001683168-18-002753/0001683168-18-002753.pdf

Nasdaq yes=$10 Nasdaq no=$2

Untill Nasdaq decision SP isn't going anywhere!

"we will drop because of the farm bill wtf!"

Not the Farm Bill, Nasdaq uncertainty.

"Why didn't Garnick move Bavi forward?"

Rob Garnick was part of the problem not the solution. His quote, "I can kill a drug if I have to" should have gone into effect years ago. As PPHM's Scientific Advisor he knew perfectly well everything that was going on but he never pulled the plug and fled through the backdoor with everyone else leaving PPHM shareholders as bag holders .

$6.62 pre-market now, might get some trading shares for less this morning!

Or not.........?

Hopefully with the arrival of the Chart Video guy and his "Inner Circle" legion the SP isn't to decimated today.

Look at it as just another buying opportunity for just another trade.

"having said that still lots of potential"

Unrealized potential always seems to be the case with this company then and now......

but lets just give it some time, yea right!

It's the same pattern. A guy shows up and makes an uncanny prediction. We get a low volume walk up that gets us there and everyone goes WOW, that was really cool! Then today happens and the SP retreats a $1 or more and the traders trade out and the others get caught in the trap of the higher SP and for how long this time is hard to say. Maybe chey is right about the $7.50 calls and we will get there before months end.

Who knows, just the insiders, let's ask them.

"Best of luck chey! May all your trades be profitable!"

Hope you were able to get in and out with some $$$......

Wash, rinse, repeat..............

Nothings changed here, still Three Card Monte just far less shills!

Well gee, that didn't last long. As to your earlier question as to who is behind the SP manipulation. It's the dopey looking guy in the back seat of my profile picture and the mastermind is driving the SP wherever he likes.

I had said when the stock got to $6 I wouldn't trash a certain group and when it got over $7 I would change my profile picture back. Let's just say the pro's are responsible, take your pick......

or how about this,The Stock Market "Organized Crime at it's Best"!

It's simply amazing how they can get an algo machine to churn all those shares in AH and have it appear all this trading activity is going on to set this thing up for a trade. The other possibility, a lot of idiots with shares in the $8 to $9 range.

The prize goes to chey for $9+ sale in AH!

Let's hope to revisit $9 sometime this year!

"It feels like we’re living in an alternate reality."

Quite a stealth move. Not one momo player here posting yet.

It's all so very odd.